ZURA

Zura Bio Ltd

4.04

Oct 30 • 3:59 PM ET +0.19 (4.94%)

4.04

Aftermarket • 7:38 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: AVTX ATTO TRAX EVMN MLTX ZBIO ANAB CTNM IMNM CMMB

| Held by: IWM VXF IWO VTWO FESM IWC SBIO VTWG AVSC GSSC

Scroll to Statements

Index	RUT
Market Cap	389.15M
Enterprise Value	201.50M
Income	-122.23M
Sales	0.00M
Book/sh	1.84
Cash/sh	1.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	Sep 03, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.19
P/C	2.07
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.29
Current Ratio	11.29
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.25
EPS next Y	-0.76
EPS next Q	-0.20
EPS this Y	22.41%
EPS next Y	7.14%
EPS next 5Y	6.07%
EPS past 3/5Y	80.48% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-76.37%
Sales Y/Y TTM	-
EPS Q/Q	4.58%
Sales Q/Q	-
Earnings	Oct 27 BMO
EPS/Sales Surpr.	1.91% -

Insider Own	47.45%
Insider Trans	0.00%
Inst Own	59.66%
Inst Trans	8.89%
ROA	-72.21%
ROE	-85.51%
ROIC	-68.80%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.14%
SMA50	-13.36%
SMA200	-22.84%
Trades

Shs Outstand	96.31M
Shs Float	50.62M
Short Float	13.87%
Short Ratio	2.69
Short Interest	7.02M
52W High	7.44 -45.70%
52W Low	3.25 24.31%
Volatility	16.34% 11.99%
ATR (14)	0.46
RSI (14)	48.10
Beta	0.02
Rel Volume	1.56
Avg Volume	2.61M
Volume	4,078,533

Perf Week	20.24%
Perf Month	-2.42%
Perf Quarter	-26.81%
Perf Half Y	-22.46%
Perf YTD	-22.90%
Perf Year	7.73%
Perf 3Y	-17.72%
Perf 5Y	-59.07%
Perf 10Y	-
Recom	1.00
Target Price	18.83
Prev Close	3.85
Price	4.04
Change %	4.94%

Consensus

Strong Buy

Avg. Price Target

$18.83

Implied Upside

+366.1%

Analysts10incl. previous ratings

Rating Distribution9 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 08, 2026	Initiated	WWilliam Blair	Outperform
Feb 09, 2026	Initiated	WWedbush	Outperform	$15	+271.3%
Nov 04, 2024	Initiated	LLeerink Partners	Outperform	$15	+271.3%
Sep 05, 2024	Initiated	HH.C. Wainwright	Neutral	$5	+23.8%
May 03, 2024	Initiated	PPiper Sandler	Overweight	$26	+543.6%
Oct 10, 2023	Initiated	LLadenburg Thalmann	Buy	$10	+147.5%
Aug 25, 2023	Initiated	OOppenheimer	Outperform	$17	+320.8%
Jun 22, 2023	Initiated	GGuggenheim	Buy	$20	+395.0%
Jun 14, 2023	Initiated	CChardan Capital Markets	Buy	$14	+246.5%
May 24, 2023	Initiated	RRaymond James	Strong Buy	$20	+395.0%

Oct-27-26 06:00PM	Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +19.94%
07:30AM	Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire)
Oct-07-26 04:00AM	This biotech stock is a top pick at Guggenheim (Investing.com) +5.30%
Aug-31-26 04:30PM	Zura Bio to Participate in the Cantor Global Healthcare Conference (Business Wire)
Aug-21-26 07:57PM	Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.69%
07:30AM	Loading…
Aug-11-26 07:30AM	Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire)
Jun-29-26 07:30AM	Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program (Business Wire) +5.23%
May-14-26 07:30AM	Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-13-26 07:30AM	Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer (Business Wire)
May-07-26 07:30AM	Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire) -7.16%
May-04-26 04:05PM	Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-19-26 04:05PM	Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates (Business Wire) -10.13%
Mar-06-26 09:31PM	UniFirst, Elastic NV, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-05-26 06:30AM	Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress (Business Wire)
Mar-02-26 06:30AM	Zura Bio to Participate in Upcoming Investor Conferences (Business Wire)
06:30AM	Loading…
Feb-27-26 06:30AM	Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (Business Wire)
Feb-25-26 06:30AM	Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants (Business Wire)
Feb-24-26 04:01PM	Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants (Business Wire)
Feb-23-26 06:30AM	Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors (Business Wire) +5.32%
Feb-16-26 06:03AM	Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 (MarketBeat)
Feb-04-26 06:30AM	Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit (Business Wire)
Jan-21-26 08:50AM	Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer (Business Wire) +26.15%
Jan-12-26 06:30AM	Zura Bio Reports Business Updates and Outlook for 2026 (Business Wire)
Nov-29-25 01:26AM	Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress (Insider Monkey)
Nov-13-25 06:30AM	Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire) -9.72%
Aug-20-25 06:30AM	Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference (Business Wire)
Aug-14-25 08:15AM	Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire) +8.18%
Jul-17-25 04:30PM	Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +51.94%
Jul-01-25 06:30AM	Zura Bio Announces Chief Financial Officer Transition (Business Wire)
May-27-25 06:30AM	Zura Bio to Present at the Jefferies Global Healthcare Conference (Business Wire)
06:30AM	Loading…
May-20-25 06:30AM	Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa (Business Wire)
May-08-25 06:30AM	Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
Mar-25-25 06:30AM	Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates (Business Wire) +10.37%
Feb-24-25 06:30AM	Zura Bio to Present at the Leerink Partners Global Healthcare Conference (Business Wire)
Dec-23-24 06:30AM	Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis (Business Wire)
Nov-25-24 06:30AM	Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +12.09%
Nov-14-24 04:30PM	Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis (Business Wire) -17.81% -12.22%
Nov-07-24 06:30AM	Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire)
Oct-30-24 06:30AM	Zura Bio to Participate in Two Upcoming Investor Conferences in November (Business Wire)
Sep-03-24 06:00AM	Zura Bio to Present at Three Upcoming Investor Conferences in September (Business Wire)
Aug-13-24 09:21AM	Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Aug-12-24 04:05PM	Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants (Business Wire)
Aug-09-24 04:05PM	Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants (Business Wire)
Aug-01-24 08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jul-12-24 06:10AM	Zura Bio Commences Warrant Exchange Offer and Consent Solicitation (Business Wire) -6.08%
06:08AM	The 3 Most Undervalued Biotech Stocks to Buy in July 2024 (InvestorPlace)
Jun-14-24 06:00AM	Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024 (Business Wire)
Jun-06-24 06:00AM	Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology (Business Wire) -8.11%
Jun-03-24 06:00AM	Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024 (Business Wire) -7.05%
May-31-24 09:55AM	Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know (Zacks)
May-29-24 06:00AM	Zura Bio Announces Participation in June Investor Conferences (Business Wire)
May-24-24 06:18AM	3 Penny Stocks to Buy Now: May 2024 (InvestorPlace)
May-15-24 09:55AM	How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84% (Zacks)
May-14-24 12:00PM	Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know (Zacks) +7.72%
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-10-24 03:14PM	Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments (GuruFocus.com)
May-09-24 01:56PM	ZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024 (InvestorPlace)
06:00AM	Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Apr-25-24 02:18AM	Director Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA) (GuruFocus.com) +9.37%
Apr-18-24 09:22AM	Zura Bio Announces Oversubscribed $112.5 Million Private Placement (Business Wire) +17.89%
Apr-08-24 06:00AM	Zura Bio Announces Robert Lisicki as CEO and Director (Business Wire)
Mar-28-24 11:54AM	ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023 (InvestorPlace) +10.78%
06:00AM	Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer (Business Wire)
Mar-04-24 06:00AM	Zura Bio Announces Participation at March Conferences (Business Wire)
Feb-02-24 06:00AM	Zura Bio Announces Participation at February Investor Conferences (Business Wire) +6.11%
Jan-08-24 06:00AM	Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO (Business Wire)
Jan-03-24 06:00AM	Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit (Business Wire)
Dec-04-23 06:00AM	Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok (Business Wire)
Nov-14-23 06:00AM	Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors (Business Wire) +10.00%
Nov-13-23 06:30AM	Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights (Business Wire) -6.54%
Sep-12-23 05:00AM	Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute (Business Wire)
Sep-05-23 08:55PM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Aug-25-23 09:42AM	Netflix upgraded, Olaplex downgraded: Wall Street's top analyst calls (The Fly)
Aug-14-23 07:00AM	Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights (Business Wire)
Jun-23-23 06:30AM	Zura Bio to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -5.69%
Jun-06-23 06:34AM	Daily Vickers Top Buyers & Sellers for 06/06/2023 (Argus Research) +16.80%
04:00AM	Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist (Business Wire)
Jun-01-23 10:20AM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +10.82%
Apr-27-23 07:39AM	Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases (Business Wire)
Apr-14-23 05:00AM	Zura Bio Announces Appointment of Chief Scientific Officer (Business Wire)
Mar-27-23 09:35AM	Zura Bio Limited Announces Share Redemptions and Lock-up Agreement (Business Wire) -42.76%
Mar-21-23 06:13AM	Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp (Business Wire) -11.27%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SOMEIT SIDHU	Director	Aug 18 '26	Proposed Sale	5.75	50,000	287,712		Aug 18 05:52 PM
SOMEIT SIDHU	Director	Aug 17 '26	Proposed Sale	5.61	27,000	151,343		Aug 17 05:41 PM
SOMEIT SIDHU	Director	Aug 14 '26	Proposed Sale	5.51	40,000	220,540		Aug 14 04:36 PM
SOMEIT SIDHU	Director	Aug 13 '26	Proposed Sale	5.63	51,000	287,043		Aug 13 05:08 PM
AI Biotechnology LLC	10% Owner	Feb 26 '26	Buy	6.25	2,000,000	12,500,000	6,552,725	Mar 02 05:55 PM

Zura Bio Ltd. is a clinical-stage, multi-asset immunology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Co-FounderDr. Sandeep Chidambar Kulkarni M.D.

COOMs. Kimberly Ann Davis J.D.

Ph.D.Dr. Kiran Nistala MBBS

VP of Finance & Accounting and Principal Financial & Accounting OfficerMs. Marlyn Mathew

Chief Technology OfficerDr. Gary Whale Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZURA

Zura Bio Ltd

Upgrade your Finviz experience